Differences

This shows you the differences between two versions of the page.

--- covid-19_vaccines:adverse_events:myopericarditis [2022/01/21 20:48]
robin [COVID-19 Vaccine Associated Myopericarditis]
+++ covid-19_vaccines:adverse_events:myopericarditis [2022/01/22 22:33] (current)
robin [Peer-Reviewed Scientific papers regarding COVID-19 Vaccine Associated Myopericarditis]
@@ Line 1: / Line 1: @@
-====== COVID-19 Vaccine Associated Myopericarditis ======
+====== COVID-19 Vaccine Associated Myopericarditis and Perimyocarditis ======
 See also: [[covid-19_vaccines:adverse_events:myocarditis|CoVid-19 Vaccine Associated Myocarditis]] and [[covid-19_vaccines:adverse_events:pericarditis|CoVid-19 Vaccine Associated Pericarditis]]
+Myopericarditis refers to inflammation of the pericardium and myocarditis. Myopericarditis is sometimes used interchangeably with perimyocarditis.
+>Myopericarditis is used when there are primarily pericarditis symptoms with evidence of the involvement of the myocardium as evidenced by cardiac biomarker elevation or imaging studies revealing normal wall motion. If there is evidence of regional wall motion abnormalities with reduced ventricular function, the term perimyocarditis has been used. [[https://www.ncbi.nlm.nih.gov/books/NBK534776/|Manda YR, Baradhi KM. Myopericarditis. [Updated 2021 Jul 26]]]
 ===== Summary from the CDC =====
@@ Line 7: / Line 11: @@
 [[https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-08-30/03-COVID-Su-508.pdf|Myopericarditis following COVID-19 vaccination: Updates from the Vaccine. Adverse Event Reporting System (VAERS). CDC Aug 30, 2021.]]
- 2,574 reports of myopericarditis or pericarditis to VAERS (as of August 18, 2021)
-• 1,903 myopericarditis, 671 pericarditis
+  * 2,574 reports of myopericarditis or pericarditis to VAERS (as of August 18, 2021)
+    * 1,903 myopericarditis, 671 pericarditis
- Epidemiology of myopericarditis following COVID-19 vaccination similar to
-previously reported updates
-• Primarily in younger males, after dose 2 mRNA vaccination, symptom onset clustering within several days of vaccination
+  * Epidemiology of myopericarditis following COVID-19 vaccination similar to previously reported updates
+    * Primarily in younger males, after dose 2 mRNA vaccination, symptom onset clustering within several days of vaccination
- Limited follow-up information in VAERS case reports suggests most patients
-(77%) recovered from symptoms at time of report or follow-up
- Observed vs. Expected analysis with VAERS reports
+  * Limited follow-up information in VAERS case reports suggests most patients (77%) recovered from symptoms at time of report or follow-up
-• Males: Observed > Expected in age groups through 49 years
-• Females: Observed > Expected in age groups through 29 years
- Enhanced surveillance for myocarditis outcomes after mRNA COVID-19
+  * Observed vs. Expected analysis with VAERS reports
-vaccination in VAERS case reports is ongoing
+    * Males: Observed > Expected in age groups through 49 years
+    * Females: Observed > Expected in age groups through 29 years
-===== Peer-Reviewed Scientific papers regarding COVID-19 Vaccine Associated Lymphadenopathy =====
+  * Enhanced surveillance for myocarditis outcomes after mRNA COVID-19 vaccination in VAERS case reports is ongoing
+===== Peer-Reviewed Scientific papers regarding COVID-19 Vaccine Associated Myopericarditis =====
 [[https://www.sciencedirect.com/science/article/pii/S002234762100665X|Myopericarditis after Pfizer mRNA COVID-19 vaccination in adolescents ]]
@@ Line 71: / Line 74: @@
 [[https://pubmed.ncbi.nlm.nih.gov/34133825/|Myopericarditis in a previously healthy adolescent male after COVID-19 vaccination: Case report]]
+[[https://journals.lww.com/pidj/Abstract/9000/Transient_Cardiac_Injury_in_Adolesce nts_Receiving.95800.aspx|Transient cardiac injury in adolescents receiving the BNT162b2 mRNA COVID-19 vaccine ]]
+===== Peer-Reviewed Scientific papers regarding COVID-19 Vaccine Associated Perimyocarditis =====
+[[https://academic.oup.com/jpids/advance-article/doi/10.1093/jpids/piab060/6329543|Perimyocarditis in adolescents after Pfizer-BioNTech COVID-19 vaccine]]
+[[https://pubmed.ncbi.nlm.nih.gov/34319393/|Perimyocarditis in adolescents after Pfizer-BioNTech COVID-19 vaccine]]
+[[https://pubmed.ncbi.nlm.nih.gov/34447639/|Unusual presentation of acute perimyocarditis after modern SARS-COV-2 mRNA-1237 vaccination]]
+[[https://bmccardiovascdisord.biomedcentral.com/articles/10.1186/s12872-021-02183|Perimyocarditis after the first dose of mRNA-1273 SARS-CoV-2 (Modern) mRNA-1273 vaccine in a young healthy male: case report]]
+[[https://pubmed.ncbi.nlm.nih.gov/34515024/|Acute perimyocarditis after the first dose of COVID-19 mRNA vaccine]]
+[[https://pubmed.ncbi.nlm.nih.gov/34866957/|Perimyocarditis after vaccination with COVID-19]]
+[[https://www.ncbi.nlm.nih.gov/pubmed/34866957|Perimyocarditis Following COVID-19 Vaccination. Clin Med Insights Cardiol]]
+[[https://www.ncbi.nlm.nih.gov/pubmed/34270752]Weighing the Risks of Perimyocarditis With the Benefits of SARS-CoV-2 mRNA Vaccination in Adolescents. J Pediatric Infect Dis Soc]]
+[[https://www.ncbi.nlm.nih.gov/pubmed/34447639Unusual Presentation of Acute Perimyocarditis Following SARS-COV-2 mRNA-1237 Moderna Vaccination. Cureus]]
+[[https://www.ncbi.nlm.nih.gov/pubmed/34348657|Perimyocarditis following first dose of the mRNA-1273 SARS-CoV-2 (Moderna) vaccine in a healthy young male: a case report. BMC Cardiovasc Disord]]